Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Time to Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE)’s share price hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $46.03 and last traded at $46.75, with a volume of 88698 shares traded. The stock had previously closed at $43.32.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on PLSE. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a report on Friday, July 17th. Canaccord Genuity Group raised their target price on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a research note on Monday. Finally, Mizuho set a $45.00 price target on Pulse Biosciences in a report on Monday. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $41.00.

Pulse Biosciences Trading Up 4.3%

The stock has a market cap of $3.13 billion, a price-to-earnings ratio of -38.28 and a beta of 1.61. The firm has a fifty day simple moving average of $30.12 and a 200-day simple moving average of $24.32.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.07). The business had revenue of $0.43 million for the quarter, compared to analyst estimates of $0.53 million. Pulse Biosciences had a negative return on equity of 100.22% and a negative net margin of 6,755.78%. On average, equities analysts predict that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pulse Biosciences

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. bought a new position in shares of Pulse Biosciences in the second quarter valued at $40,672,000. Deutsche Bank AG bought a new position in Pulse Biosciences during the second quarter worth about $687,000. Bank of New York Mellon Corp acquired a new position in Pulse Biosciences during the second quarter worth approximately $1,196,000. GSA Capital Partners LLP bought a new stake in Pulse Biosciences in the second quarter valued at approximately $290,000. Finally, Bank of America Corp DE lifted its position in shares of Pulse Biosciences by 8.2% in the first quarter. Bank of America Corp DE now owns 866,061 shares of the company’s stock valued at $18,698,000 after buying an additional 65,884 shares during the last quarter. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.